Rheos spins immunometabolism platform into deal with Roche

Roche has teamed up with Rheos Medicine in a deal that lends validation to the emerging theory that immune cell reprogramming has big therapeutic potential.

Rheos Medicine Inc. will receive $42.5 million up front from Roche (SIX:ROG; OTCQX:RHHBY) plus up to about $90 million in research and preclinical development milestones and option fees. Rheos is eligible for $660 million in development, regulatory and sales milestones, and tiered royalties...